Publication:
Discovery of novel CYP17 inhibitors for the treatment of prostate cancer with structure-based drug design

dc.contributor.departmentDepartment of Chemical and Biological Engineering
dc.contributor.departmentDepartment of Industrial Engineering
dc.contributor.departmentGraduate School of Sciences and Engineering
dc.contributor.kuauthorArmutlu, Pelin
dc.contributor.kuauthorKavaklı, İbrahim Halil
dc.contributor.kuauthorÖzdaş, Şule Beyhan
dc.contributor.kuauthorÖzdemir, Muhittin Emre
dc.contributor.kuauthorTürkay, Metin
dc.contributor.schoolcollegeinstituteCollege of Engineering
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF SCIENCES AND ENGINEERING
dc.date.accessioned2024-11-09T23:57:32Z
dc.date.issued2009
dc.description.abstractIt has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.issue5
dc.description.openaccessNO
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipTurkish Academy of Science Young Scholar Program (TUBA-GEBIP) We would like to thank Professor R. Auchus for kindly providing us cDNA of human CYP17. MT thanks IBM Corporation for providing computing hardware support through IBM SUR Award. IHK thanks the support from Turkish Academy of Science Young Scholar Program (TUBA-GEBIP).
dc.description.volume6
dc.identifier.doi10.2174/1570180810906050337
dc.identifier.eissn1875-628X
dc.identifier.issn1570-1808
dc.identifier.scopus2-s2.0-67650555893
dc.identifier.urihttps://doi.org/10.2174/1570180810906050337
dc.identifier.urihttps://hdl.handle.net/20.500.14288/15313
dc.identifier.wos268218000004
dc.keywordsProstate cancer
dc.keywordsAndrogen biosynthesis
dc.keywordsCytochrome P450 enzyme 17r-hydroxylase-17
dc.keywords20-Lyase
dc.keywordsVirtual screening
dc.keywordsHuman P450c17
dc.keywords3-beta-hydroxysteroid dehydrogenase
dc.keywordsAndrogen synthesis
dc.keywordsIn-vitro
dc.keywordsThiazolidinediones
dc.keywordsModel
dc.language.isoeng
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofLetters In Drug Design & Discovery
dc.subjectChemistry
dc.subjectMedicinal
dc.titleDiscovery of novel CYP17 inhibitors for the treatment of prostate cancer with structure-based drug design
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorArmutlu, Pelin
local.contributor.kuauthorÖzdemir, Muhittin Emre
local.contributor.kuauthorÖzdaş, Şule Beyhan
local.contributor.kuauthorKavaklı, İbrahim Halil
local.contributor.kuauthorTürkay, Metin
local.publication.orgunit1GRADUATE SCHOOL OF SCIENCES AND ENGINEERING
local.publication.orgunit1College of Engineering
local.publication.orgunit2Department of Chemical and Biological Engineering
local.publication.orgunit2Department of Industrial Engineering
local.publication.orgunit2Graduate School of Sciences and Engineering
relation.isOrgUnitOfPublicationc747a256-6e0c-4969-b1bf-3b9f2f674289
relation.isOrgUnitOfPublicationd6d00f52-d22d-4653-99e7-863efcd47b4a
relation.isOrgUnitOfPublication3fc31c89-e803-4eb1-af6b-6258bc42c3d8
relation.isOrgUnitOfPublication.latestForDiscoveryc747a256-6e0c-4969-b1bf-3b9f2f674289
relation.isParentOrgUnitOfPublication8e756b23-2d4a-4ce8-b1b3-62c794a8c164
relation.isParentOrgUnitOfPublication434c9663-2b11-4e66-9399-c863e2ebae43
relation.isParentOrgUnitOfPublication.latestForDiscovery8e756b23-2d4a-4ce8-b1b3-62c794a8c164

Files